KODIAK SCIENCES INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.82 USD | -4.02% |
|
+9.63% | +27.30% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 208M |
|---|---|---|---|---|---|
| Net income 2024 * | -225M | Net income 2025 * | -267M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 58.45M | Net cash position 2025 * | 8.2M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.97
x | P/E ratio 2025 * |
-1.05
x | Employees | 111 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kodiak Sciences Inc.
More recommendations
More press releases
| 1 day | -4.52% | ||
| 1 week | +9.63% | ||
| Current month | +20.56% | ||
| 1 month | -9.79% | ||
| 3 months | -26.57% | ||
| 6 months | +95.45% | ||
| Current year | +27.30% |
1 week
3.47
4.08
1 month
3.174.64
Current year
2.877.77
1 year
1.379.80
3 years
1.37131.97
5 years
1.37171.21
10 years
1.37171.21
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Perlroth
CEO | Chief Executive Officer | 51 | 08-12-31 |
John Borgeson
DFI | Director of Finance/CFO | 62 | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-08-31 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 19-12-16 |
Richard Levy
BRD | Director/Board Member | 66 | 18-07-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | +8.42% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 3.87 | -2.76% | 93 764 |
| 24-05-07 | 3.98 | +1.02% | 425,463 |
| 24-05-06 | 3.94 | +4.51% | 557,995 |
| 24-05-03 | 3.77 | +1.89% | 305,707 |
| 24-05-02 | 3.7 | +4.82% | 243,800 |
Delayed Quote Nasdaq, May 08, 2024 at 12:01 pm EDT
More quotes
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.98
USD
Average target price
4.25
USD
Spread / Average Target
+6.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.30% | 208M | |
| +3.91% | 106B | |
| +7.02% | 23.47B | |
| -14.73% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.88% | 16.78B | |
| +6.71% | 14.41B | |
| +34.64% | 12.86B | |
| +316.86% | 8.78B |
- Stock Market
- Equities
- KOD Stock